Montirelin

Summary

Montirelin (also known as NS‑3 or montirelin hydrate) is a synthetic analogue of thyrotropin‑releasing hormone (TRH) approved for prescription use in Japan. It is marketed for the treatment of disturbance of consciousness following head trauma and is administered orally. As a member of the TRH analogue family, it is intended to act on central nervous system pathways to aid recovery of alertness.

Mechanism of Action

Montirelin binds to TRH receptors in the brain with high affinity (Ki ≈ 35 nM). In rats, intravenous dosing reduced the number of available [³H]‑Me‑TRH binding sites without markedly altering the dissociation constant, indicating sustained receptor occupancy. This prolonged activation of TRH receptors is thought to modulate neuronal signaling pathways that influence arousal, cognition, and neuroprotection, supporting its proposed use in central nervous system disorders.

What the Research Shows

Pre‑clinical studies have characterized montirelin’s pharmacology and safety. A receptor‑binding study in rats showed potent brain TRH‑receptor occupancy lasting up to two hours after intravenous injection. Toxicology investigations in guinea pigs demonstrated no antigenic response, and bacterial reverse‑mutation, chromosome‑aberration, and micronucleus assays in vitro and in mice found no mutagenic activity. Repeated‑dose intravenous studies in rats identified a no‑observed‑adverse‑effect level of 0.05 mg/kg over five weeks, with higher doses producing tremor, polyuria, and reversible submandibular gland changes. Vascular irritability testing in rabbits revealed only mild periphlebitis compared with stronger irritants. Clinical data are limited to reports that montirelin was under regulatory review in Japan for consciousness recovery after head injury, with no published randomized trials.

Reported Benefits

Montirelin is intended to accelerate recovery of consciousness after traumatic brain injury by activating brain TRH receptors, which may enhance arousal and neuroprotective mechanisms. The drug’s high receptor affinity and sustained occupancy observed in animal models suggest potential efficacy for central nervous system disorders, and its lack of antigenicity and mutagenicity supports a favorable safety profile at therapeutic doses.

Limitations of the Evidence

Human efficacy evidence is sparse; no peer‑reviewed clinical trials are cited. Most data derive from animal studies, which may not translate directly to patients. Safety concerns emerge at doses above the NOAEL, including tremor, polyuria, and glandular hypertrophy in rats, and mild vascular irritation in rabbits. Regulatory status indicates approval in Japan, but broader international data are lacking.

Safety Considerations

Pre‑clinical testing shows montirelin is non‑antigenic and non‑mutagenic. Repeated intravenous dosing in rats identified a NOAEL of 0.05 mg/kg; higher doses caused tremor, polyuria, decreased weight gain, and reversible submandibular gland hypertrophy. In rabbits, intravenous administration produced mild periphlebitis and thrombus formation, indicating weak vascular irritability. Caution is warranted when extrapolating these findings to human dosing, especially at higher exposures.

How It Is Administered

Montirelin is formulated for oral administration in its approved prescription form. Pre‑clinical studies have employed intravenous dosing to assess pharmacokinetics and toxicity, but clinical use follows the oral route. The oral formulation is intended for systemic absorption to reach brain TRH receptors.

Routes of Administration

Goals & Uses

• NeuroprotectionNeurologyLow
• Disorders of consciousness / arousalNeurological / Critical CareLow
• Treatment of spinocerebellar degenerationNeurological / Movement DisordersModerate
• Pituitary function testingEndocrinology / DiagnosticModerate

Contraindications

• Thyroid disease (hyperthyroidism)EndocrineModerate
• PregnancyPopulationModeratePotential fetal risk or insufficient safety data
• Severe cardiovascular diseaseCardiovascularModerate
• Hypersensitivity to montirelin or TRH analoguesAllergy / ImmunologicHigh

Adverse Effects

• Urinary urgencyGenitourinaryUncommon
• Increased prolactin levelsEndocrineCommon
• HeadacheNeurologicUncommonPain in the head or upper neck
• FlushingVascularCommonWarmth and redness of the skin
• Increased blood pressureCardiovascularUncommon
• NauseaGastrointestinalCommonFeeling of sickness or urge to vomit

Drug Interactions

• Thyroid hormone preparations (levothyroxine)Low
• Dopamine agonists (bromocriptine, cabergoline)Low
• Antithyroid drugs (methimazole, propylthiouracil)Moderate

Population Constraints

• Hepatic impairmentOrgan FunctionRelative
• Renal impairmentOrgan ImpairmentRelative
• Pediatric patientsAgeRelative
• Elderly patientsAgeRelative

Regulatory Status

• European UnionUnapprovedNot approved by the EMA; no marketing authorization in the European Union.
• United StatesUnapprovedNot approved by the FDA; classified as investigational/research compound in the US.
• United KingdomUnapprovedNot approved by the MHRA in the United Kingdom.

Approved in Japan for spinocerebellar degeneration. Not approved by the FDA or EMA. Research and investigational use in other jurisdictions.

Evidence & Sources

• Neurosurgical trauma in Japan
  Journal ArticleModerateMaejima S, Katayama Y2001-01-01T00:00:00.000000Z
• [Antigenicity study on montirelin hydrate (NS-3)]
  Journal ArticleLowFujisawa H, Nishimura T, Kimura K1995-01-01T00:00:00.000000Z
• [Mutagenicity studies of montirelin hydrate (NS-3)]
  Journal ArticleLowIwakura K, et al.1995-01-01T00:00:00.000000Z
• Brain receptor binding characteristics and pharmacokinetic-pharmacodynamic analysis of thyrotropin-releasing hormone analogues
  Journal ArticleLowUrayama A, et al.2001-01-01T00:00:00.000000Z
• [Vascular irritability study of montirelin hydrate (NS-3) injection in rabbits]
  Journal ArticleLowShibata R, et al.1995-01-01T00:00:00.000000Z
• [Five-week intravenous toxicity study of montirelin hydrate (NS-3) in rats followed by 4-week recovery test]
  Journal ArticleLowKikumori M, et al.1995-01-01T00:00:00.000000Z

Frequently Asked Questions